{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:17:04Z","timestamp":1790381824794,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) patients frequently attain a bone marrow (BM) minimal residual disease (MRD) negativity status in response to treatment. We identified 568 patients who achieved BM MRD negativity following autologous stem cell transplantation (ASCT) and maintenance combination therapy with an immunomodulatory agent and a proteasome inhibitor. BM MRD was evaluated by next-generation flow cytometry (sensitivity of 10\u22125 cells) at 3- to 6-month intervals. With a median follow-up of 9.9 years from diagnosis (range, 0.4-30.9), 61% of patients maintained MRD negativity, whereas 39% experienced MRD conversion at a median of 6.3 years (range, 1.4-25). The highest risk of MRD conversion occurred within the first 5 years after treatment and was observed more often in patients with abnormal metaphase cytogenetic abnormalities (95% vs 84%; P\u00a0=\u00a0.001). MRD conversion was associated with a high risk of relapse and preceded it by a median of 1.0 years (range, 0-4.9). However, 27% of MRD conversion-positive patients had not yet experienced a clinical relapse, with a median follow-up of 9.3 years (range, 2.2-21.2). Landmark analyses using time from ASCT revealed patients with MRD conversion during the first 3 years had an inferior overall and progression-free survival compared with patients with sustained MRD negativity. MRD conversion correctly predicted relapse in 70%, demonstrating the utility of serial BM MRD assessment to complement standard laboratory and imaging to make informed salvage therapy decisions.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005822","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T21:01:34Z","timestamp":1637614894000},"page":"808-817","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"first","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"},{"name":"Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Kendrick","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-0614","authenticated-orcid":false,"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute of Health and Equity, Medical College of Wisconsin, Wauwatosa, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-9467","authenticated-orcid":false,"given":"Naveen","family":"Yarlagadda","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Atwal","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadav","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2509-312X","authenticated-orcid":false,"given":"Arya","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5270-104X","authenticated-orcid":false,"given":"Richa","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, LA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Arkansas for Medical Sciences, Little Rock, AR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erming","family":"Tian","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"issue":"1","key":"2022013116231293000_B1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"12","key":"2022013116231293000_B2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022013116231293000_B3","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3324\/haematol.2014.115162","article-title":"The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma","volume":"100","author":"Paiva","year":"2015","journal-title":"Haematologica."},{"issue":"1","key":"2022013116231293000_B4","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"22","key":"2022013116231293000_B5","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med."},{"key":"2022013116231293000_B6","first-page":"860","article-title":"Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM)","volume":"134","author":"Costa","year":"2019","journal-title":"Am Soc Hematol"},{"issue":"23","key":"2022013116231293000_B7","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood."},{"issue":"20","key":"2022013116231293000_B8","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood."},{"issue":"23","key":"2022013116231293000_B9","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"20","key":"2022013116231293000_B10","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022013116231293000_B11","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"8","key":"2022013116231293000_B12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022013116231293000_B13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J."},{"issue":"8","key":"2022013116231293000_B14","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022013116231293000_B15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia."},{"issue":"8","key":"2022013116231293000_B16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol."},{"issue":"2","key":"2022013116231293000_B17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","article-title":"Long-term outcomes after autologous stem cell transplantation for multiple myeloma","volume":"4","author":"Nishimura","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2022013116231293000_B18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood."},{"issue":"26","key":"2022013116231293000_B19","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood."},{"issue":"6","key":"2022013116231293000_B20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood."},{"issue":"5","key":"2022013116231293000_B21","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood."},{"issue":"7","key":"2022013116231293000_B22","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1038\/bcj.2016.64","article-title":"Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma [published correction appears in Blood Cancer J. 2016;6(9):e471]","volume":"6","author":"Jethava","year":"2016","journal-title":"Blood Cancer J."},{"issue":"15","key":"2022013116231293000_B23","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022013116231293000_B24","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood.V128.22.4431.4431","article-title":"The clinical impact of macrofocal disease in multiple myeloma differs between presentation and relapse","volume":"128","author":"Rasche","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2022013116231293000_B25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.25755","article-title":"Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco-Israeli collaborative myeloma working group","volume":"95","author":"Katodritou","year":"2020","journal-title":"Am J Hematol."},{"issue":"12","key":"2022013116231293000_B26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"issue":"10","key":"2022013116231293000_B27","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia."},{"issue":"8","key":"2022013116231293000_B28","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","article-title":"The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica."},{"key":"2022013116231293000_B29","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood-2019-131870","article-title":"Long-term outcome of total therapy regimens: impact of molecular subgroups","volume":"134","author":"van Rhee","year":"2019","journal-title":"Blood."},{"key":"2022013116231293000_B30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139943","article-title":"Late relapsing multiple myeloma \u2265 10 years after treatment on total therapy protocols are associated with good outcome","volume":"136","author":"Mohan","year":"2020","journal-title":"Blood."},{"issue":"9","key":"2022013116231293000_B31","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1002\/ajh.26255","article-title":"Persistent bone marrow minimal residual disease as a \u201chigh-risk\u201d disease feature in multiple myeloma","volume":"96","author":"Mohan","year":"2021","journal-title":"Am J Hematol."},{"issue":"6","key":"2022013116231293000_B32","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol."},{"issue":"3","key":"2022013116231293000_B33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","article-title":"High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis","volume":"110","author":"van Rhee","year":"2007","journal-title":"Blood."},{"issue":"19","key":"2022013116231293000_B34","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","article-title":"The impact of response kinetics for multiple myeloma in the era of novel agents","volume":"3","author":"Yan","year":"2019","journal-title":"Blood Adv."},{"issue":"5","key":"2022013116231293000_B35","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/bloodadvances.2018022806","article-title":"Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma","volume":"3","author":"Tandon","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"2022013116231293000_B36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia."},{"issue":"12","key":"2022013116231293000_B37","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal flow cytometry identified \u201cminimal residual disease\u201d (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"23","key":"2022013116231293000_B38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 Trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022013116231293000_B39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022013116231293000_B40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/hematology.2019000075","article-title":"Evidence-based minireview: does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?","volume":"2019","author":"Sidana","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"5","key":"2022013116231293000_B41","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","article-title":"Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study","volume":"20","author":"Kunacheewa","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"2022013116231293000_B42","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41409-020-0791-y","article-title":"Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma","volume":"55","author":"Patel","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"2022013116231293000_B43","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2019-131887","article-title":"EARLY results of TOTAL therapy 7 (TT7): high response rates of NEWLY diagnosed high risk myeloma to daratumumab","volume":"134","author":"van Rhee","year":"2019","journal-title":"Blood."},{"key":"2022013116231293000_B44","first-page":"8507","article-title":"Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with\/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211) [abstract]","volume-title":"J Clin Oncol","author":"Usmani","year":"2020"},{"issue":"6","key":"2022013116231293000_B45","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"2022013116231293000_B46","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022013116231293000_B47","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood."},{"key":"2022013116231293000_B48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-142298","article-title":"The bone marrow microenvironment of multiple myeloma long-term survivors at single cell resolution","volume":"136","author":"Lutz","year":"2020","journal-title":"Blood."},{"key":"2022013116231293000_B49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-136258","article-title":"Discordances between immunofixation (IFx) and minimal residual disease (MRD) assessment with next-generation flow (NGF) and sequencing (NGS) in patients (Pts) with multiple myeloma (MM): clinical and pathogenic significance","volume":"136","author":"Rodr\u00edguez","year":"2020","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/808\/1866120\/advancesadv2021005822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/808\/1866120\/advancesadv2021005822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T16:24:00Z","timestamp":1643646240000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/808\/482725\/Clinical-implications-of-loss-of-bone-marrow"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005822","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}